Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Diagnostic Patterns and Clinical Characteristics of Hereditary ATTR Amyloidosis: A Retrospective Study From a U.S. Health System
Neuromuscular and Clinical Neurophysiology (EMG)
P6 - Poster Session 6 (5:00 PM-6:00 PM)
9-008

To evaluate real-world diagnostic and treatment patterns of hereditary transthyretin(hATTR) amyloidosis across an urban U.S. health system. 
Hereditary transthyretin (hATTR) amyloidosis is a progressive, multisystem disease caused by pathogenic TTR mutations. Despite its prevalence in certain populations—particularly among African Americans with the V142I variant, real-world data remain limited. As gene-silencing therapies such as vutrisiran, and eplontersen become more widely available, characterizing diagnostic and treatment patterns is critical.
We conducted a five-year retrospective review across the MedStar Health system. Patients with diagnostic codes for both neuropathy and amyloidosis were identified from electronic health records. Following manual chart review, 63 individuals met criteria for confirmed hATTR amyloidosis. Data were extracted on demographics, TTR genotypes, biopsy status, EMG, neurology and cardiology consultations, and use of disease-modifying therapies.
The median age was 78 years; the cohort was 89% African American and 94% non-Hispanic. Genetic testing was performed in 98%, with V142I found in 81%. Biopsy confirmation was present in 35%, and EMG was completed in 56%. Neurology and cardiology consultations were documented in 79% and 97%, respectively. Tafamidis alone was prescribed in 43%, tafamidis plus siRNA agents in 13%, tafamidis plus eplontersen in 6%, siRNA alone in 5%, and ASO alone in 2%. About 32% received no disease-modifying therapy.

In this diverse, urban cohort, V142I was predominant. Many patients lacked full diagnostic workup or treatment, underscoring disparities in care. These findings are especially relevant given the expanding role of gene-silencing therapies in hATTR management. 
Authors/Disclosures
Nicholas S. Streicher, MD
PRESENTER 		Dr. Streicher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion . Dr. Streicher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovent. Dr. Streicher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Streicher has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. Dr. Streicher has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion.
Hermela A. Wubet, MD Dr. Wubet has nothing to disclose.